Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of Depigoid pollen combinations in allergic rhinitis or rhinoconjunctivitis
2012-001699-12Phase 2Active
- Sponsor
- LETI Pharma
- Start
- Aug 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Depigoid in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), seasonal allergic rhinitis (SAR) and 1 more (2 arms), sponsored by LETI Pharma. Primary endpoint: Subjects with at least one grade 2 or higher systemic reaction. Started Aug 2012; status: active.
02
Drugs
Depigoid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)seasonal allergic rhinitis (SAR)asthma
Beyond the preview
Go deeper on 2012-001699-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001699-12.